Compare Immunovant Inc. Common Stock (IMVT) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs The Coca-Cola Co K — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while The Coca-Cola Co K trades at $87.38 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 60.4× Immunovant Inc. Common Stock's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and The Coca-Cola Co K for 154 Days on average.
| IMVT | KO | |
|---|---|---|
Market Cap | $6.25B | $377.63B |
Volume | 1,755,411 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $44.96 | $91.99 |
52-Week Low | $17.03 | $66.37 |
Typical Hold Time | 0 Days | 154 Days |
Enterprise Value | $5.35B | $404.81B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations. KO maintains robust profitability with 61.89% gross margins and 28.56% net income margins, supported by steady revenue growth and a dominant market position.
The stock presents a compelling dividend opportunity with 64 consecutive years of increases, though technical indicators suggest near-term pressure. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential. Key risks include regional demand divergence and high valuation multiples that may limit short-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
